Experts

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

John C. Andrews, Ph.D. Director of Regulatory Affairs, Americas, Chiltern, a global CRO. For more information, visit chiltern.com. Jerome Bailey. VP, Early Phase Business Center, Omnicare Clinical Research, a full-service CRO with diverse therapeutic expertise and comprehensive clinical service offerings. For more information, visit omnicarecr.com. Hal Barron. Global Head, Product Development and Chief Medical Officer, Roche, a research-focused healthcare company with combined strengths in pharmaceuticals and diagnostics. For more information, visit rocheusa.com. Patricia Bassett. VP Sales EMEA, Unithink, a provider of solutions to pharmaceutical and biotech clients. For more information, visit ­unithink.com. John Benbrook. CEO, MMG Inc., a full-service patient recruitment and retention group. For more information, visit wegetpatients.com. Nancy L. Boman, M.D., Ph.D. VP, Clinical Development and Regulatory Affairs, Acucela Inc., a clinical-stage biotechnology company focused on developing new methods for treating blinding eye diseases. For more information, visit acucela.com. Paul Boni. Chief Research Officer, Grail Research, which combines strategic consulting with market research to provide organizations with accurate, succinct answers to their most important business questions. For more information, visit grailresearch.com. Kathy Bronshtein. Senior VP, Chief Compliance Officer, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com. Eddie Caffrey. Global Head, Phase I, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com. Patrick Chassaigne. Director, Late Phase Solutions, Medidata Solutions, a global provider of hosted clinical development solutions that enhance the efficiency of clinical development processes. For more information, visit mdsol.com. Clare Colletti. VP and Managing Director, Global Commercialization, inVentiv Advance Insights, the strategic planning and consultative arm of inVentiv Health. For more information, visit inventivhealth.com. Alan Copa, Pharm.D. President, Clinical Operations, Cetero Research, a CRO providing early-phase research services. For more information, visit cetero.com. William H. Crown, Ph.D. President, i3 Innovus, a provider of health economics and outcomes research and market informatics solutions. For more information, visit i3global.com. Stephen Cutler, Ph.D. Senior VP and Chief Operating Officer, Kendle, a global CRO providing a full range of development services. For more information, visit kendle.com. Ed Damp. Chief Operating Officer, BioPath ­Consulting LLC, a specialty company focusing on scientific and clinical training and education of the salesforce. For more information, ­biopathconsulting.com. Jamie Dananberg, M.D. Executive Director of Clinical Pharmacology, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com. Fran L. DeGrazio. VP, Marketing and Strategic Business Development, West Pharmaceutical Services Inc., a global provider of standard-setting systems and device components for parenterally administered medicines. For more information, visit westpharma.com. James DeSanti. Founder and CEO, Pharma­Vigilant, a clinical trial technology provider. For more information, visit pharmavigilant.com. Natalie Douglas. CEO, Idis, which develops and implements prelaunch named patient programs. For more information, visit idispharma.com. Murray Ducharme, Pharm.D. Chief Science Officer, Cetero Research, a CRO specializing in early-phase research services. For more information, visit cetero.com. James D. Esinhart Ph.D. Executive VP, Global Biometrics & North America Business Unit, Chiltern, a global CRO. For more information, visit chiltern.com. Dave Evans. Chief Information Officer, Octagon Research Solutions Inc., a provider of software and services to the life-sciences industry. For more information, visit octagonresearch.com. Martha Feller, Ph.D. Global Executive VP, Operations, i3 Research, a full-service, global CRO therapeutically focused on CNS, oncology, respiratory and infectious diseases, endocrinology and metabolic diseases, and cardiology. For more information, visit i3global.com. Trevor Fitzpatrick. VP and General Manager, Medical Communications Services, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com. Jens Oliver Funk, M.D. Senior VP and Global Head of TA Oncology, EMD Serono Inc., an affiliate of Merck KGaA, is a U.S. biopharmaceutical company that specializes in neurodegenerative diseases, fertility, metabolic endocrinology, and oncology. For more information, visit emdserono.com. Jean-Jacques Garaud, M.D. Global Head, Pharmaceutical Research and Early Development, Roche, research-focused healthcare company with combined strengths in pharmaceuticals and diagnostics. For more information, visit rocheusa.com. Chip Gillooly. VP, Capital, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com. Mark A. Goldberg, M.D. Chief Operating Officer, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com. John R. Hall. Global Medical Affairs, Epidemiology and Outcomes Research, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com. Kevin Hrusovsky. President and CEO, Caliper Life Sciences, provides technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. For more information, visit caliperls.com. Nigel Hughes. Founder and Director, Firecrest Clinical, a clinical technology organization that brings together experts in clinical trials, pharmacy, medicine, communications, and technology to create Web-hosted solutions. For more information, visit firecrestclinical.com. Loni Jakub. Manager, ViewPoint Implementation Services, Octagon Research Solutions Inc., a provider of software and services to the life-sciences industry. For more information, visit octagonresearch.com. Thomas W. Jones, Ph.D. Senior Director, Toxicology and Pathology, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com. R. Shane Kennedy. Executive VP, Managing Director, Sudler Digital, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com. Steve Kent. President, Perceptive Informatics, an e-clinical solutions provider and subsidiary of Parexel International Corp. For more information, visit perceptive.com. Darshan Kulkarni, Pharm.D., Esq. Principal Attorney, Kulkarni LLC, a law firm that advises pharmaceutical companies and their service providers on bringing their products to market. For more information, visit conformlaw.com. Laurie Lucas. Founder and Principal, L3 Healthcare Marketing, a strategic healthcare communications and marketing company specializing in market conditioning for novel products and technologies. For more information, visit l3hm.com. Howard Mayer, M.D. Chief Medical Officer, EMD Serono Inc., an affiliate of Merck KGaA, is a U.S. biopharmaceutical company that specializes in neurodegenerative diseases, fertility, metabolic endocrinology, and oncology. For more information, visit emdserono.com. Troy McCall, Ph.D. CEO, Cetero Research, a CRO providing early-phase research services. For more information, visit cetero.com. Kalpana Merchant, Ph.D. Chief Scientific Officer, the Translational Science Group, Eli Lilly and Company, which is developing a growing portfolio of pharmaceutical products. For more information, visit lilly.com. Donna Michalizysen. Managing Partner, Precept Medical Communications, a healthcare education and communications company and a Sudler & Hennessey/WPP company. For more information, e-mail donna.michalizysen@ preceptmedical.com. Michelle Middle, MB CH.B. Corporate VP and Worldwide Head of Early Phase, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com. Doreen Moran. Senior Digital Strategist, Sudler Digital, Sudler & Hennessey, a healthcare communications firm. For more information, visit sudler.com. Mario R. Nacinovich Jr. Managing Director, Axon Communications, a specialist healthcare consulting firm, and Editor-in-Chief, Journal of Communication in Healthcare. For more information, visit axon-com.com or maney.co.uk/index.php/ journals/cih. Michael Naimoli. U.S. Life Sciences Industry Solutions Director, Microsoft Corp., a global technology company. For more information, visit microsoft.com. Robert A. Norris. Founder and President, Complete Healthcare Communications Inc., a strategic medical communications agency that specializes in publication planning. For more information, visit chcinc.com. Michael Parisi. President, Altum, a CommonHealth freestanding, full-service, professional advertising and promotion company with global reach, spanning every marketing discipline with a focus on high-science and specialty markets. For more information, visit commonhealth.com. Brian Sanderson, M.D. Medical Director, Chiltern Early Phase, a global CRO. For more information, visit chiltern.com. Kerri A. Schoedel, Ph.D. Scientific Director, Clinical Pharmacology, Kendle, a global CRO providing the full range of development services. For more information, visit kendle.com. David Selkirk. Senior Director, Clinimetrics, a global full-service CRO that supports the complete spectrum of clinical trials. For more information, visit clinimetrics. com. Nancy Smerkanich. Executive VP, Global Regulatory Affairs, Octagon Research Solutions, a provider of software and services to the life-sciences industry. For more information, visit octagonresearch.com. Peter Smith, Ph.D. Senior VP, Nonclinical Development Sciences, Millennium: The Takeda Oncology Company, biopharmaceutical company focused exclusively in oncology to improve the treatment of cancer around the world. For more information visit millennium.com. Sean Smith. VP, Logistics and Asia, Fisher Clinical Services, provides products and services to support supply-chain needs within a clinical-trial setting. For more information, visit fisherclinicalservices.com. Nagaraja Srivatsan. VP and Head of Life Sciences, North America, Cognizant, a provider of consulting, technology, and business process outsourcing services. For more information, visit ­cognizant.com. Alain Stricker-Krongrad, Ph.D. Chief Scientific Officer, Charles River, which provides essential products and services to help pharmaceutical and biotechnology companies accelerate their research and drug development efforts. For more information, visit criver.com. Barbara Tardiff, M.D. Corporate VP, Parexel International Corp., a global biopharmaceutical services organization. For more information, visit parexel.com. Anne Tomalin. President, i3 CanReg, provides regulatory affairs consulting for the pharmaceutical, biotechnology, and medical-device industries. For more information, visit i3global.com. Scott Treiber. Executive VP, Clinical Development Solutions, inVentiv Clinical Solutions, which provides clinical trial management and monitoring, biostatistics, and data management solutions; regulatory consulting and liaison services; and patient and investigator recruitment, complemented by industry-leading staffing capabilities. For more information, visit inventivclinical.com. Jeff Trotter. Executive VP – Phase IV Development, PharmaNet, a global drug development services company that provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical-device industries. For more information, visit pharmanet.com. Cynthia Verst, Pharm.D. Senior VP, Late Phase Research, i3 Innovus, a provider of health economics and outcomes research and market informatics solutions. For more information, visit i3global.com. Robin L. Winter-Sperry, M.D. President and CEO, Scientific Advantage LLC, consulting firm specializing in medical affairs, medical information, and medical science liaison teams, and Science Oriented Solutions (SOS), a full-service contract MSL company. For more information, visit scientificadvantage.com or scienceorientedsolutions.com. Stuart Young. Executive VP, Clinical Monitoring, Chiltern, a global CRO. For more information, visit chiltern.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK